Abstract
IntroductionWe report week-52 results from an open-label extension that assessed the efficacy and safety of adalimumab (ADA) in anti-TNF–naïve patients with moderately to severely active ulcerative colitis (UC).MethodsPatients were adults...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have